THE HOST RESPONSE IN GRAFT-VERSUS-HOST DISEASE .3. THE IN-VITRO INDUCTION OF REGULATORY CELLS IN CHRONIC MURINE GRAFT-VERSUS-HOST DISEASE

被引:3
|
作者
MANN, RA
SINGH, AB
JETZT, AE
SINGH, M
机构
[1] Division of Nephrology, Department of Medicine, University of Medicine, Dentistry of New Jersey-Robert Wood Johnson, New Brunswick
关键词
D O I
10.1006/cimm.1995.1136
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Murine graft versus host (GVH) disease takes two forms depending upon the parental/F1 strain combination employed, Acute lethal GVH disease is characterized by anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third-party alloantigen. In contrast to this, chronic GVH disease is characterized by polyclonal B cell activation, autoantibody production, no anti-F1 cytotoxicity, and retained cytotoxicity against allotargets. We have previously reported that this marked disparity in disease expression results from a radiosensitive host cell which protects the F1 mouse from parental anti-F1 CTX in mice undergoing CGVH disease, Using an in vitro system to induce the host protective cell, we now demonstrate that two distinct Thy-1(+) cells emerge which regulate CTX against the host. One cell is of host origin, radiation sensitive, and functionally resembles a veto cell, The second regulatory cell, of parental origin, is radiation resistant and restricted in its ability to suppress anti-F1 CTX: We further demonstrate that the emergence of these cells is modulated by competitive immunoregulatory influences mediated by T contrasuppressor and I-J(+) cells. (C) 1995 Academic Press, Inc.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Rehabilitation in Chronic Graft-Versus-Host Disease
    Smith, Sean Robinson
    Asher, Arash
    PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA, 2017, 28 (01) : 143 - +
  • [42] Effects of Pravastatin on Murine Chronic Graft-Versus-Host Disease
    Yoon, Hyoung-Kyu
    Lim, Ji-Young
    Kim, Tae-Jung
    Cho, Chul-Soo
    Min, Chang-Ki
    TRANSPLANTATION, 2010, 90 (08) : 853 - 860
  • [43] Ruxolitinib for Chronic Graft-versus-Host Disease
    Shibusawa, Motoharu
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (17): : 1631 - 1631
  • [44] The pathophysiology of chronic graft-versus-host disease
    Kansu, E
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (03) : 209 - 215
  • [45] Therapy of chronic graft-versus-host disease
    Arora, Mukta
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (02) : 271 - 279
  • [46] Management of Chronic Graft-Versus-Host Disease
    Baker, Melissa
    McKiernan, Phyllis
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2011, 15 (04) : 429 - 432
  • [47] The pathophysiology of chronic graft-versus-host disease
    Emin Kansu
    International Journal of Hematology, 2004, 79 : 209 - 215
  • [48] THE BIOLOGY OF CHRONIC GRAFT-VERSUS-HOST DISEASE
    DEEG, HJ
    EXPERIMENTAL HEMATOLOGY, 1985, 13 : 128 - 130
  • [49] The Treatment of Chronic Graft-Versus-Host Disease
    Wolff, Daniel
    Bertz, Hartmut
    Greinix, Hildegard
    Lawitschka, Anita
    Halter, Joerg
    Holler, Ernst
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2011, 108 (43): : 732 - I
  • [50] Development of chronic graft-versus-host disease
    Slayback, DL
    Dobkins, JA
    Harper, JM
    Allen, RD
    FASEB JOURNAL, 2000, 14 (06): : A1074 - A1074